News stories about Charles River Laboratories International (NYSE:CRL) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Charles River Laboratories International earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.3968555323698 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Shares of Charles River Laboratories International (NYSE CRL) opened at C$102.12 on Friday. The stock has a market cap of $4,836.61, a price-to-earnings ratio of 20.06, a P/E/G ratio of 1.64 and a beta of 0.94. Charles River Laboratories International has a fifty-two week low of C$69.51 and a fifty-two week high of C$119.05. The company has a quick ratio of 1.49, a current ratio of 1.88 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, November 9th. The company reported C$1.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of C$1.22 by C$0.08. The firm had revenue of C$464.23 million during the quarter, compared to analysts’ expectations of C$458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. Charles River Laboratories International’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.18 earnings per share. analysts anticipate that Charles River Laboratories International will post 5.12 EPS for the current fiscal year.

Several equities analysts have weighed in on the stock. ValuEngine cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday. Bank of America Corporation lowered their price target on shares of Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, August 11th. BidaskClub upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Finally, Jefferies Group LLC boosted their price target on shares of Charles River Laboratories International from $120.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 9th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of C$105.77.

TRADEMARK VIOLATION WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/12/charles-river-laboratories-international-crl-earns-news-impact-score-of-0-15.html.

In related news, insider Davide Molho sold 6,165 shares of the company’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of C$110.00, for a total value of C$678,150.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of C$67.10, for a total transaction of C$171,239.20. Following the completion of the sale, the insider now owns 11,671 shares of the company’s stock, valued at C$783,124.10. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 10,500 shares of company stock valued at $2,885 and sold 18,699 shares valued at $1,892,393. Corporate insiders own 2.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.